drugset
drugset / Trial / NCT06927687

Study of ZG005 in Patients With Advanced Solid Tumors

NCT06927687 ↗

Phase 2 Active not recruiting 50 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.

Timeline

Start
2025-06-13
Primary completion
2027-05
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG005 Unknown 20 mg/kg Intravenous

Indications

neoplasm